Author

A. Davidoff

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Organism:human· 3 Organism:mouse· 3 Approach:statistical model· 3 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

J. Fang· 5 shared J. Yang· 5 shared H. Jin· 4 shared S. Singh· 4 shared A. Murphy· 3 shared R. Wang· 3 shared D. Hu· 2 shared G. Turner· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 42 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersCancer Biology

J. Fang

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

RBM39 degrader invigorates natural killer cells to eradicate neuroblastoma despite cancer cell plasticity

S. Singh, J. Fang, H. Jin, L.-A. Van de Velde, Q. Wu, A. Cortes, C. Morton, M. Woolard, W. Quarni, J. Steele, J. Connelly, L. He, R. Thorne, G. Turner, T. Confer, , J. Yang

This study shows that targeting RBM39 with indisulam promotes natural killer cell activity and eradicates neuroblastoma regardless of cellular state plasticity.

bioRxiv · Mar 21, 2024 · PreprintCancer Biology

Conditional c-MYC activation in catecholaminergic cells drives distinct neuroendocrine tumors: neuroblastoma vs somatostatinoma

J. YANG, T. Wang, L. Liu, J. Fang, H. Jin, S. Natarajan, H. Sheppard, M. Lu, G. Turner, T. Confer, M. Johnson, J. Steinberg, L. Ha, N. Yadak, R. Jain, , R. Wang

This study creates two mouse models with conditional c-MYC activation in specific cell types, leading to distinct neuroendocrine tumors resembling human neuroblastoma and somatostatinoma.

bioRxiv · Mar 12, 2024 · PreprintCancer Biology

Metabolic reprogramming of cancer cells by JMJD6-mediated pre-mRNA splicing is associated with therapeutic response to splicing inhibitor

J. YANG, C. M. Jablonowski, W. Quarni, S. Singh, H. Tan, D. H. Bostanthirige, H. Jin, J. Fang, T.-C. Chang, D. Finkelstein, J.-H. Cho, D. Hu, V. Pagala, S. M. Sakurada, S. M. Pruett-Miller, , G. Wu

This study shows JMJD6 links pre-mRNA splicing and metabolism in MYC-driven cancers, and its inhibition enhances therapeutic response to splicing inhibitors.

bioRxiv · Jun 26, 2023Cancer Biology

KDM6B promotes activation of the oncogenic CDK4/6-pRB-E2F pathway by maintaining enhancer activity in MYCN-amplified neuroblastoma

A. D'oto, J. Fang, H. Jin, B. Xu, S. Singh, A. Mullasseril, V. Jones, X. Von Butler, B. Cooke, D. Hu, J. Shohet, A. Murphy, A. Davidoff, J. YANG

This study shows KDM6B promotes oncogenic CDK4/6-pRB-E2F pathway activation in neuroblastoma by maintaining enhancer activity, and its inhibition correlates with poor patient survival.

bioRxiv · Jul 2, 2020Cancer Biology

Geldanamycin inhibits Jumonji histone lysine demethylase KDM4 and targets chimeric transcription factor PAX3-FOXO1

A. Abu-Zaid, S. Singh, W. LIN, J. Low, A. Abdolvahabi, B. Bailey Cooke, J. Bowling, S. Vaithiyalingam, J. Fang, D. Currier, M.-K. Yun, A. AlTahan, D. Fernando, J. Maier, H. Tillman, , J. YANG

This study identifies geldanamycin and its analog 17-DMAG as dual KDM/Hsp90 inhibitors effective against PAX3-FOXO1-driven rhabdomyosarcoma.

bioRxiv · Dec 11, 2019 · PreprintCancer Biology